The Role of 5α-Reductase Inhibitors (5-ARIs) in Prostate Cancer Chemoprevention
Prostate cancer, due to its high prevalence and long latency period, is an ideal candidate for prevention. Considerable effort has been placed on prevention strategies utilizing 5α-reductase inhibitors (5-ARIs). In this chapter, we will review the rationale and key studies examining the role of these drugs in primary and secondary prevention of prostate cancer.
KeywordsProstate Cancer Gleason Score Active Surveillance Prostate Volume Pathologic Progression
- 9.Wilt T, MacDonald R, Hagerty K, et al. 5-α reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008; 2: Art no.CD007091.Google Scholar
- 19.Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, REDEEM Study Group. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007;28(6):763–9.PubMedCrossRefGoogle Scholar
- 20.Fleshner N, Lucia MS, Melich K, Nandy I, Black L, Rittmaster R. Dutasteride reduces prostate cancer progression and cancer diagnosis on re-biopsy in the REDEEM active surveillance study. Abstract SUO. 2010.Google Scholar